Fox Run Management’s Fulgent Genetics FLGT Stock Holding History

Fox Run Management’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,992	Closed	-$236K	–	1005
2025 Q4	$236K	Buy	+8,992	New	+$233K	0.04%	758

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fox Run Management's FLGT Position: Q1 2026 in Review

Fox Run Management sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 8,992 shares — an estimated $236K sold.

Fox Run Management first reported a position in FLGT in Q4 2025 and held it in 1 quarter. The position peaked at $236K in Q4 2025. 158 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

Fox Run Management reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 8,992 Fulgent Genetics shares in Q1 2026, an estimated $236K.
Fox Run Management first reported a position in Fulgent Genetics in Q4 2025 and held it in 1 quarter.
Fox Run Management's Fulgent Genetics position peaked at $236K in Q4 2025.
158 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.